Premier Alternatives

Genvax Technologies

Ames, IA · Founded 2021 · Privately Held (backing)

Developer of animal vaccines designed to accelerate treatments for the animal health industry. Genvax Technologies is based in Ames, IA and was founded in 2021. Its last reported valuation was $25 million in Aug 2022. It has raised $8.4 million across 2 recorded rounds; the latest was a $3.4 million seed round in Jun 2024.

Last reported valuation
$25.0M
Oct 2026
Priced at
—
Total raised
$8.4M
Last round
Seed Round
Jun 2024

Genvax Technologies key facts

as of Oct 2026
  • Developer of animal vaccines designed to accelerate treatments for the animal health industry.
  • Genvax Technologies is valued at approximately $25.0M as of Oct 2026 (last reported valuation).
  • It has raised $8.4M across 2 recorded rounds; the latest was Seed Round ($3.4M) in Jun 2024.
  • Notable investors include United States Department of Agriculture, Next Level Ventures, Ag Ventures Alliance, 1945 Capital, Ag Startup Engine — 11 tracked in total.
  • Genvax Technologies has filed 2 Form Ds with the SEC since 2022, most recently Jun 2024 ($3.4M sold to 9 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$25.0M

Genvax Technologies's last reported valuation, Aug 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Genvax Technologies with a free account
  • ·The complete investor list: 11 names
  • ·Watch Genvax Technologies: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Genvax Technologies funding rounds

2 rounds
Jun 2024Seed Round$3.4MSEC filing▮
Jun 2022Early Stage VC$6.4MSEC filing▮
Full funding history →

Genvax Technologies valuation

Genvax Technologies's last reported valuation was $25 million in Aug 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Genvax Technologies raised?

Genvax Technologies has raised $8.4 million across 2 recorded rounds since 2022. The largest was a $6.4 million early-stage round in Jun 2022; the most recent was a $3.4 million seed round in Jun 2024.

Genvax Technologies has filed 2 Form Ds with the SEC since 2022, most recently in Jun 2024 ($3.4 million sold to 9 investors).

Genvax Technologies investors

11 investors are on record for Genvax Technologies, including United States Department of Agriculture, Next Level Ventures, Ag Ventures Alliance and 1945 Capital. The seed round in Jun 2024 drew 9 investors.

About Genvax Technologies

Developer of animal vaccines designed to accelerate treatments for the animal health industry. The company's saRNA platform allows for the rapid development of herd or flock-specific vaccines matched to the variant strain circulating in an animal-production operation by inserting a specific transgene or gene of interest matched to the variant strain into the platform, providing clients from the animal health industry with novel vaccines for the prevention and treatment of animal diseases.

Sector
Business Products and Services (B2B)
HQ
Ames, IA, United States
Founded
2021
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.